StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Ovid Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -2178.9%. For fiscal 2025 it was -240.1%, against -4670.1% the year before. The highest annual figure on record is 58.9% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-240.1%+4430.0
FY2024Dec 31, 2024-4670.1%+8681.6
FY2023Dec 31, 2023-13351.8%−9747.1
FY2022Dec 31, 2022-3604.7%−3663.6
FY2021Dec 31, 202158.9%+701.2
FY2020Dec 31, 2020-642.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2047.6%+5825.5
Q4 FY2025Dec 31, 20251345.8%+13520.8
Q3 FY2025Sep 30, 2025-9210.6%−1114.7
Q2 FY2025Jun 30, 2025-74.7%−5116.7
Q1 FY2025Mar 31, 2025-7873.1%+28.3
Q4 FY2024Dec 31, 2024-12175.0%−1384.9
Q3 FY2024Sep 30, 2024-8096.0%+2227.9
Q2 FY2024Jun 30, 20245042.0%+21586.0
Q1 FY2024Mar 31, 2024-7901.4%+12335.0
Q4 FY2023Dec 31, 2023-10790.1%+14069.0
Q3 FY2023Sep 30, 2023-10323.9%+97474.5
Q2 FY2023Jun 30, 2023-16544.0%−15429.5
Q1 FY2023Mar 31, 2023-20236.4%−20320.8
Q4 FY2022Dec 31, 2022-24859.1%−24472.8
Q3 FY2022Sep 30, 2022-107798.3%−107560.8
Q1 FY2022Mar 31, 2022-1114.5%–
Q1 FY2021Mar 31, 202184.5%–
Q4 FY2020Dec 31, 2020-386.3%–
Q3 FY2020Sep 30, 2020-237.6%–

More Ovid Therapeutics figures

See a number that looks wrong?